Research & Development



  “控球和投籃是宿主原本應該擁有的出色的能力,但宿主自身在上個世界籃球能力太差,無法發揮出這兩個技能,現在宿主開始訓練,這兩個原本的能力將有機會激活,這需要宿主自身能力值提高或者用5張技能升級卡激活。”   但現在,阿蘭?休斯頓還沒有受傷,30歲的他正值巔峰,狂人和馬克?杰克遜雖老,但對于老鷹隊來說還是很棘手的。色妊阁伊人在线   “哈哈,我沒有艾斯你那樣的投籃天賦,我要多練練,讓我的罰球不要那麼爛,就不會被砍鯊戰術擊敗了!”穆罕穆德笑道,並沒有在意自己是不是先來。伊人在线猫   “嘿,和小孩子說什麼!我可是老師!那些事就別提了。”亞莉克希婭老師打斷了劉莽。   “……”劉莽那個悲催,稀有物品啊!稀有!他想要死在小蘿莉懷里的心都有了……大香蕉网伊人在线4   終于,黛娜睡著了。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo